Company Description
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific.
The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions.
The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
| Country | Israel |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Marvin L. Slosman |
Contact Details
Address: 4 Menorat Hamaor St. Tel Aviv, L3 6744832 Israel | |
| Phone | (888) 776-6804 |
| Website | inspiremd.com |
Stock Details
| Ticker Symbol | NSPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001433607 |
| CUSIP Number | 45779A853 |
| ISIN Number | US45779A8466 |
| Employer ID | 26-2123838 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Marvin L. Slosman | President, Chief Executive Officer and Director |
| Craig Shore | Chief Financial Officer, Chief Administrative Officer, Secretary and Treasurer |
| Andrea Tommasoli | Chief Operating Officer |
| Amir Kohen | Vice President of Finance and Human Resources |
| Shane Thomas Gleason | Chief Commercial Officer |
| Dr. Patrick A. Verta DVM, M.D., MS Stat | Executive Vice President of Clinical and Medical Affairs |
| Pete Ligotti | Executive Vice President and GM of North America |
| Dr. Sol J. Barer Ph.D. | Special Advisor to the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | ARS | Filing |
| Apr 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 18, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 6, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 10-K | Annual Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |